Using microfluidic shear to assess transfusion requirements in trauma patients by Rachael A Callcut, James T Ross, Anamaria J Robles, Leslie H Vuoncino, Ashli C Barnes, Leonardo W Graeff, Taylor L Anway, Nico T Vincent, Nithya Tippireddy, Kimi M Tanaka, Randi J Mays

Get full text

Reconsidering “Critical” Bone Loss in Shoulder Instability: 17-Year Follow-Up Study following Arthroscopic Bankart Repair by Lawrence Chun-Man Lau, Wai-Wang Chau, Randy Ng, Jonathan Patrick Ng, Elvis Chun-Sing Chui, Michael Tim-Yun Ong, James Francis Griffith, Patrick Shu-Hang Yung

Get full text

Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation by Vera V, Sheybani A, Panarelli JF, Grover DS, Lee J, Craven ER, Samuelson TW, Ahmed IIK

“…Vanessa Vera,1 Arsham Sheybani,2 Joseph F Panarelli,3 Davinder S Grover,4 James Lee,5 Earl Randy Craven,2 Thomas W Samuelson,6 Iqbal Ike K Ahmed7 1Allergan, an AbbVie company, Irvine, CA, USA; 2Washington University School of Medicine, St Louis, MO, USA; 3Department of Ophthalmology, New York University Langone Health, New York, NY, USA; 4Glaucoma Associates of Texas, Dallas, TX, USA; 5Colorado Eye Institute, Colorado Springs, CO, USA; 6Minnesota Eye Consultants, University of Minnesota, Minneapolis, MN, USA; 7John Moran Eye Center, University of Utah, Salt Lake City, UT, USACorrespondence: James Lee, Colorado Eye Institute, Colorado Springs, CO, 80924, USA, Email jlee@eyescolorado.comAbstract: The XEN® 45 Glaucoma Treatment System (gel stent; Allergan, an AbbVie company, Irvine, CA, USA) is a minimally invasive bleb-forming surgical device that was originally approved to lower intraocular pressure by diverting the aqueous humor from the anterior chamber to the subconjunctival space (like trabeculectomy) following ab-interno placement. …”
Get full text